Portal de Periódicos da CAPES

Seroepidemiology of Human Bocavirus Defined Using Recombinant Virus-Like Particles

2008; Oxford University Press; Volume: 198; Issue: 1 Linguagem: Inglês

10.1086/588674

1537-6613

Jeffrey S. Kahn, Deniz Kesebir, Susan F. Cotmore, Anthony D’Abramo, Christi N. Cosby, Carla Weibel, Peter Tattersall,

Immunodeficiency and Autoimmune Disorders

Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined.The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA.Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals >or=48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened.HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection.